Tension Headache: What Could Be Causing It

How Common Is Tension-Type Headache?

Tension-type headache is the single most prevalent neurological disorder on the planet, yet it receives a fraction of the research funding directed toward migraine. A 2007 Lancet Neurology review calculated a global one-year prevalence of 38.3%, with episodic forms vastly outnumbering chronic ones [1]. The condition affects women slightly more than men, with a female-to-male ratio near 5:4 across most population-based surveys.

The Global Burden of Disease Study 2019 ranked TTH as the third most prevalent condition worldwide (behind dental caries and latent tuberculosis), responsible for significant years lived with disability [2]. Despite this ranking, many patients never seek medical care. A Danish population study found that only 16% of people with frequent episodic TTH had consulted a physician for the problem [3]. That gap between burden and treatment-seeking creates a large pool of self-medicating individuals, some of whom drift into medication-overuse headache without realizing it.

Prevalence peaks between ages 30 and 39, then gradually declines. Children are not spared. School-based surveys in Europe report TTH prevalence between 10% and 25% in adolescents, often co-occurring with academic stress and screen time [3]. The economic consequences are substantial: lost workdays and reduced productivity from TTH cost the European economy an estimated €21.6 billion annually, according to a 2012 analysis published in the Journal of Headache and Pain [1].

What Causes Tension-Type Headache?

The origin of TTH involves both peripheral muscle mechanisms and changes in central pain processing, though the relative contribution of each shifts depending on whether the headache is episodic or chronic. Peripheral sensitization of myofascial nociceptors in pericranial muscles (temporalis, frontalis, trapezius, sternocleidomastoid) is the primary driver in episodic TTH, while central sensitization at the level of the trigeminal nucleus caudalis and higher cortical areas dominates in chronic forms [4].

Pericranial tenderness on manual palpation is the most consistent physical finding. A controlled study published in Cephalalgia demonstrated that Total Tenderness Scores were significantly higher in TTH patients than in headache-free controls (P<0.001), and that tenderness increased with headache frequency and intensity [4]. The International Headache Society's ICHD-3 classification specifically distinguishes TTH subtypes based on whether pericranial tenderness is present [5].

Several trigger categories have been identified through prospective diary studies:

Musculoskeletal strain. Sustained postures (desk work, phone use, driving) generate tonic contraction in cervical and pericranial muscles. Electromyographic studies show elevated trapezius activity in TTH patients during computer work compared to matched controls [4].

Psychosocial stress. Stress is the most frequently self-reported trigger, cited by 80% to 90% of TTH patients in survey data [6]. The mechanism likely involves both increased muscle tension and hypothalamic-pituitary-adrenal axis activation, though the exact pathway remains under investigation.

Sleep disturbance. Both insufficient and excessive sleep correlate with increased TTH frequency. A cross-sectional analysis in the journal Headache found that sleeping fewer than 6 hours per night doubled the odds of chronic TTH (OR 2.0 to 95% CI 1.2 to 3.2) [6].

Medication overuse. Using simple analgesics on 15 or more days per month, or triptans/opioids on 10 or more days per month, can transform episodic TTH into a chronic daily headache pattern. The ICHD-3 criteria designate this as a distinct entity: medication-overuse headache [5].

How Is Tension-Type Headache Diagnosed?

Diagnosis is clinical. There is no blood test, imaging study, or biomarker for TTH. The ICHD-3 criteria published by the International Headache Society require at least 10 lifetime episodes of headache lasting 30 minutes to 7 days, with at least two of the following four features: bilateral location, pressing or tightening quality, mild-to-moderate intensity, and not aggravated by routine physical activity such as walking or climbing stairs [5]. The headache must also lack both nausea/vomiting (though mild nausea is permitted in chronic TTH) and the combination of photophobia and phonophobia (one but not both is allowed).

The critical diagnostic task is not confirming TTH but ruling out secondary causes. "The most important step in headache evaluation is distinguishing primary from secondary headache disorders," wrote Dr. David Dodick in a 2018 BMJ clinical review [7]. Red flags that demand further workup include sudden thunderclap onset (peak intensity within 60 seconds), new headache after age 50, headache with fever and neck stiffness, progressive worsening over weeks, focal neurological deficits, papilledema, and headache triggered by Valsalva maneuver or positional change.

Neuroimaging (MRI with or without contrast) is not recommended for patients who meet ICHD-3 criteria for TTH and have a normal neurological examination. The American College of Radiology Appropriateness Criteria rate brain MRI as "usually not appropriate" for uncomplicated primary headache [8]. Ordering scans reflexively leads to incidental findings that generate anxiety and unnecessary follow-up procedures without improving outcomes.

A headache diary kept for at least 4 weeks is the single most useful diagnostic tool beyond history and examination. It captures frequency, duration, intensity, associated symptoms, triggers, and medication use, all of which directly inform treatment decisions and help distinguish episodic from chronic TTH.

Tension-Type Headache vs. Migraine: Key Differences

Misdiagnosis between TTH and migraine is common, partly because the two conditions frequently coexist in the same patient. A population-based study in Cephalalgia found that 62% of individuals with chronic TTH also met criteria for migraine at some point in their lives [4]. The American Migraine Foundation estimates that nearly half of all migraine patients are initially misdiagnosed, often carrying a TTH label for years.

The distinguishing features are straightforward in textbook cases. Migraine is typically unilateral, pulsating, moderate-to-severe, and aggravated by physical activity. TTH is bilateral, pressing, mild-to-moderate, and not worsened by movement. Migraine brings nausea, vomiting, photophobia, and phonophobia. TTH does not (or allows only one of the sensory sensitivities). Migraine attacks last 4 to 72 hours. TTH episodes can be as brief as 30 minutes.

Real patients complicate this picture. Some attacks land in an overlap zone with features of both. The ICHD-3 handles this by allowing dual diagnoses. A patient can carry both "frequent episodic TTH" and "migraine without aura" simultaneously, with each attack classified individually based on its features [5].

"If the headache is disabling, think migraine first," noted Dr. Peter Goadsby in a Lancet Neurology review on headache classification [9]. This heuristic is clinically useful: TTH rarely forces a person to stop what they are doing. If a patient reports missing work or retreating to a dark room, the diagnosis is more likely migraine regardless of how the pain quality is described.

Acute Treatment Options

The goal of acute therapy is complete pain freedom within two hours, with no recurrence within 24 hours. For episodic TTH, first-line treatment is a simple analgesic taken early in the attack.

Ibuprofen 400 mg is the best-studied option. A Cochrane systematic review (2015) of 12 randomized controlled trials found that ibuprofen 400 mg provided at least 50% pain relief at two hours in 55% of participants versus 25% for placebo (NNT 3.2) [10]. This makes it the most effective single-dose OTC option for TTH.

Acetaminophen 1 to 000 mg is an alternative when NSAIDs are contraindicated (renal impairment, peptic ulcer disease, anticoagulant use). The same Cochrane group reported a two-hour pain relief rate of 59% versus 39% for placebo (NNT 5.0) for the 1 to 000 mg dose, while the 500 mg dose was not significantly better than placebo [11].

Aspirin 1 to 000 mg shows efficacy similar to ibuprofen in head-to-head trials, though gastrointestinal tolerability is slightly worse [10].

Combination analgesics (acetaminophen plus caffeine, for example) improve efficacy marginally but carry a higher risk of medication-overuse headache with regular use. Caffeine adjuvant (65 to 200 mg) reduces the NNT by approximately 1 when added to acetaminophen [11].

Opioids have no role in TTH management. They are not more effective than NSAIDs for this indication, carry addiction risk, and strongly promote medication-overuse headache. The American Academy of Neurology's 2021 practice advisory explicitly recommends against opioid use for primary headache disorders [12].

Preventive Therapy for Chronic Tension-Type Headache

Prevention becomes appropriate when TTH occurs 15 or more days per month, when acute medication use approaches overuse thresholds (analgesics on 15+ days or combination analgesics on 10+ days), or when attacks cause substantial disability despite optimal acute treatment.

Amitriptyline is the only preventive medication with Level A evidence for chronic TTH. A meta-analysis in the journal Headache pooled data from six RCTs and found that amitriptyline 25 to 75 mg at bedtime reduced headache frequency by 33% compared to placebo [13]. The therapeutic effect is independent of its antidepressant action and appears at lower doses than those used for depression. Common side effects include dry mouth, morning drowsiness, weight gain, and constipation. Starting at 10 mg and titrating slowly over 4 to 6 weeks improves tolerability.

Venlafaxine (150 mg daily) and mirtazapine (15 to 30 mg at bedtime) have shown benefit in smaller trials and are considered second-line options when amitriptyline is not tolerated [13]. "Amitriptyline remains the gold standard for TTH prevention, but clinicians should individualize based on comorbidities," stated the European Federation of Neurological Societies guideline on TTH management [14].

Non-pharmacologic approaches have growing evidence. A randomized trial published in BMJ (2017) compared manual therapy (physiotherapy with cervical and thoracic mobilization) to usual care and found a 2.3-day reduction in monthly headache days over 26 weeks [7]. Cognitive behavioral therapy targeting stress management and maladaptive coping reduced headache frequency by approximately 50% in a 2019 meta-analysis of eight trials [6]. Acupuncture, while controversial, was rated as "probably effective" by Cochrane reviewers after pooling 12 trials with 2,349 participants, showing a small but statistically significant benefit over sham acupuncture for chronic TTH [15].

Physical exercise (aerobic training 3 times per week for 40 minutes) reduced chronic TTH frequency by 1.5 days per month versus a non-exercise control group in a Scandinavian trial, with additional benefits for mood and sleep quality [6].

Medication-Overuse Headache: The Hidden Trap

One of the most clinically important complications of TTH is its transformation into medication-overuse headache (MOH). The ICHD-3 defines MOH as headache occurring 15 or more days per month in a patient with a pre-existing headache disorder who has been overusing acute headache medication for more than 3 months [5]. The global prevalence of MOH is approximately 1% to 2%, but among patients presenting to headache clinics, rates reach 30% to 50%.

The mechanism involves a paradoxical increase in central sensitization driven by repeated analgesic exposure. All acute headache medications can cause MOH, but the risk varies by drug class. Opioids and combination analgesics (especially those containing butalbital) carry the highest risk, producing MOH with as few as 10 use-days per month. Simple analgesics like ibuprofen or acetaminophen require more frequent use (15+ days/month) to trigger MOH [12].

Treatment requires withdrawal of the overused medication. This can be done abruptly (preferred for simple analgesics) or gradually (advisable for opioids and butalbital). A bridging preventive (amitriptyline or topiramate) is typically started simultaneously. A prospective study in Cephalalgia found that 73% of MOH patients reverted to an episodic headache pattern within 6 months of successful withdrawal [4].

The best strategy is prevention. Patients with episodic TTH should receive clear guidance at the first visit: limit acute analgesic use to no more than 2 days per week, and track medication days with a diary.

When to Seek Urgent Evaluation

Most tension-type headaches are benign, self-limiting, and manageable with over-the-counter medication and lifestyle adjustment. A small fraction of headache presentations, however, signal conditions that require immediate medical attention.

The mnemonic "SNOOP4" (developed by Dr. David Dodick) captures the major red flags [7]:

• Systemic symptoms (fever, weight loss, cancer history, HIV)
• Neurologic signs (confusion, weakness, vision changes, seizures)
• Onset sudden (thunderclap: maximal intensity within seconds)
• Older age (new headache after age 50)
• Positional component (worse lying down or standing)
• Progressive pattern (worsening over days to weeks)
• Precipitated by Valsalva (cough, strain, exertion)
• Papilledema on fundoscopy

Any of these findings in a patient presenting with headache requires neuroimaging (typically MRI brain with and without gadolinium) and, in some scenarios, lumbar puncture [8]. A thunderclap headache mandates CT head followed by CT angiography or lumbar puncture to exclude subarachnoid hemorrhage, even if the initial CT is normal.

Patients with chronic daily headache who fail two or more preventive trials should be referred to a headache specialist or neurologist for re-evaluation of the diagnosis, assessment for comorbidities (depression, anxiety, sleep apnea, temporomandibular disorder), and consideration of advanced therapies. The Endocrine Society and American Academy of Neurology both recommend screening for hypothyroidism in patients with refractory chronic headache, as subclinical thyroid dysfunction can mimic or worsen TTH [12].